Welcome to our home for news – the latest headlines, all in one place. Click through to view a selection of our media coverage, industry news, videos and more.
Join the Botanix commercial team and guests for the Company’s Commercial Day Webinar on Tuesday 17 September 10:30am AEST / 8:30am AWST for a comprehensive update on commercial launch plans and market insights for Sofdra™.
https://botanixpharma.com/wp-content/uploads/webinar.png8501600Haley Chartres/wp-content/uploads/botanix-logo.pngHaley Chartres2024-09-11 04:44:262024-09-11 04:44:2617 September Commercial Day Webinar – Registration Open
To view Appendix 4E, click here. Mark your calendar for the Company’s Commercial Day Webinar on Tuesday 17 September 10:30am AEST / 8:30am AWST which will provide a comprehensive update on commercial launch plans and market insights for Sofdra™. Registration to follow.
https://botanixpharma.com/wp-content/uploads/Annual-report-1.png8501600Haley Chartres/wp-content/uploads/botanix-logo.pngHaley Chartres2024-08-30 12:49:002024-08-30 20:06:19Appendix 4E Released and Commercial Day Webinar Announced
Per E&P analyst David Nayagam, Sofdra is poised to provide a new treatment option for primary axillary hyperhidrosis, with “a novel and potentially disruptive model for marketing, reimbursement and distribution.” E&P affirms Speculative Buy and $0.55 Price Targe
Euroz Hartleys’ Seth Lizee asserts that “the market opportunity for Sofdra is significant.” Hyperhidrosis is the third largest dermatology condition in the USA with approx. ~10m patients with axillary hyperhidrosis.” Upgraded to Buy and $0.47 Price Target.
Botanix has received firm commitments for $70 million capital raising via an institutional placement. Funds will be applied towards the launch of Sofdra™ (sofpironium) gel, 12.45%, as well as working capital and costs of the placement.
https://botanixpharma.com/wp-content/uploads/Cap-Raise.png8501600Haley Chartres/wp-content/uploads/botanix-logo.pngHaley Chartres2024-06-21 01:37:462024-06-21 01:37:46Botanix secures commitments for $70 million
17 September Commercial Day Webinar – Registration Open
/in ASX Releases, Featured, Latest News, News /by Haley ChartresJoin the Botanix commercial team and guests for the Company’s Commercial Day Webinar on Tuesday 17 September 10:30am AEST / 8:30am AWST for a comprehensive update on commercial launch plans and market insights for Sofdra™.
Pre-register: Click here
Appendix 4E Released and Commercial Day Webinar Announced
/in ASX Releases, Featured, Latest News, News /by Haley ChartresTo view Appendix 4E, click here. Mark your calendar for the Company’s Commercial Day Webinar on
Tuesday 17 September 10:30am AEST / 8:30am AWST which will provide a comprehensive update on
commercial launch plans and market insights for Sofdra™. Registration to follow.
“Potentially Disruptive” | E&P Analysis
/in Featured, Latest News, News /by Haley ChartresPer E&P analyst David Nayagam, Sofdra is poised to provide a new treatment option for primary axillary hyperhidrosis, with “a novel and potentially disruptive model for marketing, reimbursement and distribution.” E&P affirms Speculative Buy and $0.55 Price Targe
View Report.
Euroz Hartleys Upgrades BOT to Buy
/in Featured, Latest News /by Haley ChartresEuroz Hartleys’ Seth Lizee asserts that “the market opportunity for Sofdra is significant.” Hyperhidrosis is the third largest dermatology condition in the USA with approx. ~10m patients with axillary hyperhidrosis.” Upgraded to Buy and $0.47 Price Target.
View Report.
Botanix secures commitments for $70 million
/in ASX Releases, Featured, Latest News, News /by Haley ChartresBotanix has received firm commitments for $70 million capital raising via an institutional placement. Funds will be applied towards the launch of Sofdra™ (sofpironium) gel, 12.45%, as well as working capital and costs of the placement.
View ASX release.
FDA Approves Sofdra™ topical gel
/in ASX Releases, Featured, Latest News, News /by Haley Chartres